Mallinckrodt has executed a definitive settlement agreement with Cuyahoga and Summit Counties in Ohio, in connection with pending opioid litigation lawsuits.
Mallinckrodt will pay $24 million in cash and provide $6 million in generic products, including addiction treatment products, thereby fully resolving all “Track 1 Cases,” currently scheduled to go to trial in October 2019.
All named Mallinckrodt entities will be dismissed with prejudice from the lawsuit.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze